TSI Investor Profile: ABcann
Featured Video
Company Brief
Licensed since March 2014, ABcann sets itself apart from other Canadian licensed producers with its 94% customer retention rate, its focus on organic cultivation in proprietary growing chambers and its industry-leading production yields in excess of 250 grams per sq. ft., double the industry average.
The company, which is in the process of developing its 65-acre site with a second 150K sq. ft. facility, has a research partnership with the University of Guelph and and has supplied innovative cannabis inhaler device maker Syqe Medical with its standardized cannabis.
Summary
Fiscal Year-End: December
License Renewal Month: October 2017
Licenses: 1
Licensed Capacity: 625 kilograms
Number of Patients: N/A
Headquarters: Napanee, Ontario
Financials (pro forma 09/30)
Cash on hand: $28.9mm
Fixed Investment: $5.72mm
Shareholders’ Equity: $17.8mm
Revenues – Last Quarter: N/A
Adj. Gross Margin: N/A
EPS: N/A
Capital Structure (04/23/17)
Last Financing: 12.875mm shares at $0.80
Basic Shares: 97.20mm
Warrants: 39.71mm
Options: 9.41mm
Diluted Shares: 173.83mm
Highlights
- Focus on pharmaceutical grade plant standardization
- 94.7% customer retention rate
- Organic production using exclusive, computer-controlled environmental system
Growth Strategy
- Expand existing facility and construct 2nd facility targeting 40 kg/annum production capacity
- Pursue global initiatives in Europe, Israel and Australia
- Active discussions to license production to U.S. operators
Differentiators
- Production through computer-controlled environmental systems
- Industry-leading efficiency in terms of yield per square foot
- Research partnership with University of Guelph
Above Industry Average Yields
ABcann’s standardized organic growing methods yield not only a higher quality product as reflected by its premium pricing but also a lower overall cost. According to PI Financial, ABcann is able to produce almost double the industry average as measured by grams per square foot.
Strong Advisory Board Led by
the “Father of Cannabis Medicine”
Dr. Raphael Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. Mechoulam is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.
Related Articles
Interview with ABcann Global (OTC: ABCCF TSX.V: ABCN) CEO Aaron Keay
The Seed Investor sits down with ABcann CEO Aaron Keay to discuss ABcann and what it takes to be the strongest grower in the Marijuana sector.
The strategic approach of ABcann’s growth technique
Aaron Keay, CEO of ABcann Global Corporation, speaks with Natasha Frakes about why the company waited two years from getting their license before going public.
InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Takes Additional Step toward Clinical Trials for INM-750
Moving toward offering the very first therapy for treating epidermolysis bullosa (EB), InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) recently announced it has signed an agreement with Pharmaseed Ltd.
Cannabis Wheaton President Talks Deal with ABcann
Cannabis Wheaton President Talks Deal with ABcann and also delves into the effect the recreational legalization will have on Cannabis Wheaton
Is Canada Ready for Legalization?
Recently the New York Times looked at the challenges facing Canada as it prepares for full legalization. The Seed Investor breaks it down for you.
Investors Eye Sweet Spots in Canada's Booming Cannabis Market
Canada is the investment mecca of the global cannabis market, boasting legalization in every province and an array of investment opportunities, such as ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF), a Canadian grower of medical marijuana.
ABcann Global Corporation (TSX.V: Abcn) (OTCQB: Abccf) Announces Close of $15 Million Investment from Cannabis Wheaton
ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the completion of Cannabis Wheaton Income Corp.’s (TSX.V: CBW) previously detailed purchase of $15 million of ABcann common shares at an agreed upon valuation of $2.25 per share.
ABcann Global Corp. (TSX.V: Abcn) (OTCQB: Abccf) Moves Closer to Kimmett Expansion with TSXV Approval of Cannabis Wheaton Investment
Cannabis Wheaton Income Corp. (TSX.V: CBW) this morning announced that it has received approval from the TSX Venture Exchange to purchase $15 million of common shares of ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) at an agreed upon valuation of $2.25 per share.
ABcann Global (TSX-V:ABCN) (Frankfurt:23Q) (OTCQB:ABCCF) Provides Construction and Expansion Update
ABcann Global Corporation (TSX-V:ABCN) (Frankfurt:23Q) (OTCQB:ABCCF) is pleased to provide an update on the Company's construction and expansion timelines for its Vanluven and Kimmett facilities, both located in Napanee, Ontario.
The strategic approach of ABcann’s growth technique
Aaron Keay, CEO of ABcann Global Corporation, speaks with Natasha Frakes about why the company waited two years from getting their license before going public.
ABcann Global Announces Listing on the OTCQB Marketplace and the Frankfurt Stock Exchange
The Company expects to benefit from being listed on the OTCQB and the FSE by gaining greater visibility and convenience of trading the Company’s common shares to US and European investors, allowing a much larger potential shareholder base and enhanced liquidity.
ABcann and Cannabis Wheaton Announce Signing of Agreement for First Tranche $15 Million Investment
ABcann Global Corporation (TSX: ABCN ) and Cannabis Wheaton Income Corp. (TSX: CBW) are pleased to announce the signing of a definitive subscription agreement pursuant to which CW has agreed to purchase $15 million of ABcann common shares at $2.25 per share.